Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: DMAA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0.19% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.95 - 10.27 | Updated Date 05/1/2025 |
52 Weeks Range 9.95 - 10.27 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Ordinary Shares
Company Overview
History and Background
Drugs Made In America Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It was incorporated in 2020.
Core Business Areas
- Acquisition: Seeking to acquire businesses in the pharmaceutical or healthcare industries, with a focus on companies that develop, manufacture, or commercialize drugs in America.
Leadership and Structure
The company is led by its CEO and a board of directors with experience in the pharmaceutical and investment industries.
Top Products and Market Share
Key Offerings
- Blank Check Company: Drugs Made In America Acquisition Corp. does not have specific products or services. Its offering is the potential acquisition target they eventually merge with. As a SPAC, it doesn't hold market share until merging.
Market Dynamics
Industry Overview
The SPAC market has seen increased activity, but also increased scrutiny. The success of a SPAC depends heavily on the quality of the acquisition target.
Positioning
Drugs Made In America Acquisition Corp. is positioned to find and acquire a promising company within the pharmaceutical or healthcare sector. Their competitive advantage is largely dependent on their management team's expertise and network.
Total Addressable Market (TAM)
The TAM is the entire US pharmaceuticals market value, estimated to be in the hundreds of billions of dollars annually. Drugs Made In America Acquisition Corp. is positioned to capture a share of this market through its eventual acquisition, if the merger is successful.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Specific industry focus (pharmaceuticals)
- Potential access to capital through public markets
Weaknesses
- No current operations or revenue
- Reliance on finding a suitable acquisition target
- Competition from other SPACs
Opportunities
- Acquisition of a high-growth pharmaceutical company
- Increased demand for domestically manufactured drugs
- Potential for regulatory tailwinds supporting US-based drug production
Threats
- Inability to find a suitable acquisition target
- Changes in market conditions affecting the pharmaceutical industry
- Increased regulation of SPACs
Competitors and Market Share
Key Competitors
- Other SPACs targeting the pharmaceutical industry
- More broadly, all other companies in the pharmaceutical sector once an acquisition is made.
Competitive Landscape
The company competes with other SPACs for attractive acquisition targets. Post-acquisition, it will compete with established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: No historical growth as a SPAC.
Future Projections: Future growth is entirely dependent on the acquired company's performance. Analyst estimates will only be available following the merger.
Recent Initiatives: Focused on identifying and evaluating potential acquisition targets in the pharmaceutical industry.
Summary
Drugs Made In America Acquisition Corp. is a SPAC with a focus on the pharmaceutical industry, making its current strength its management team's expertise. The company needs to find a suitable acquisition target to realize its potential and face threats from market volatility. The company's future depends entirely on the success of its eventual acquisition and its strategic focus.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Analysis Reports
Disclaimers:
This analysis is based on available information and is not financial advice. SPAC investments are speculative and carry significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Ordinary Shares
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-02-25 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com | ||
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.